| NCT | Title | Condition | Status | Contact |
| NCT06157892 | A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors (NCT06157892) | Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer | RECRUITING | |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (NCT04260802) | Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer, Gastric Cancer, Cervical Cancer, Ovarian Cancer, Hepatocellular Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Urothelial Neoplasm, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Locally Advanced Solid Tumor, Locally Advanced Malignant Neoplasm, Squamous Cell Carcinoma, Sarcoma, Merkel Cell Carcinoma, Bladder Cancer | RECRUITING | |
| NCT05581004 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors (NCT05581004) | Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Colorectal Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC | RECRUITING | |
| NCT04421820 | BOLD-100 in Combination with FOLFOX for the Treatment of Advanced Solid Tumours (NCT04421820) | Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma | RECRUITING | saali@ohri.ca; roleclerc@ohri.ca |
| NCT04871412 | The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III (NCT04871412) | Lung Cancer, Gastric Cancer, Esophageal Cancer | RECRUITING | |
